Review



er oxycodone hydrochloride (oxycontin)  (Purdue Pharma)

 
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 90
      Buy from Supplier

    Structured Review

    Purdue Pharma er oxycodone hydrochloride (oxycontin)
    Summary of <t> oxycodone </t> plasma PK parameters following PF614 and OxyContin administration (day 1) – part A.
    Er Oxycodone Hydrochloride (Oxycontin), supplied by Purdue Pharma, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/er oxycodone hydrochloride (oxycontin)/product/Purdue Pharma
    Average 90 stars, based on 1 article reviews
    er oxycodone hydrochloride (oxycontin) - by Bioz Stars, 2026-06
    90/100 stars

    Images

    1) Product Images from "Clinical evaluation of PF614, a novel TAAP prodrug of oxycodone, versus OxyContin in a multi‐ascending dose study with a bioequivalence arm in healthy volunteers"

    Article Title: Clinical evaluation of PF614, a novel TAAP prodrug of oxycodone, versus OxyContin in a multi‐ascending dose study with a bioequivalence arm in healthy volunteers

    Journal: Clinical and Translational Science

    doi: 10.1111/cts.13765

    Summary of oxycodone plasma PK parameters following PF614 and OxyContin administration (day 1) – part A.
    Figure Legend Snippet: Summary of oxycodone plasma PK parameters following PF614 and OxyContin administration (day 1) – part A.

    Techniques Used: Clinical Proteomics

    Part A: Semi‐log plot of mean (SD) oxycodone plasma concentrations versus time. Part A: day 1 0–12 h; Part B: day 5 0–120 h. Mean plasma concentrations of plasma oxycodone on day 1 (a) versus day 5 (b) are shown following single oral dose administrations of 50 mg, 100 mg, or 200 mg PF614, or 20 mg, 40 mg, or 100 mg OxyContin. PK concentrations were collected for 18 subjects in the PF614 group (6 subjects in each dose cohort) or six subjects in the OxyContin group (2 subjects in each dose cohort). Oxycodone mean plasma concentrations were above the LLOQ (0.200 ng/mL) within 0.50 h to 1.00 h postdose. LLOQ, lower limit of quantification; PK, pharmacokinetic.
    Figure Legend Snippet: Part A: Semi‐log plot of mean (SD) oxycodone plasma concentrations versus time. Part A: day 1 0–12 h; Part B: day 5 0–120 h. Mean plasma concentrations of plasma oxycodone on day 1 (a) versus day 5 (b) are shown following single oral dose administrations of 50 mg, 100 mg, or 200 mg PF614, or 20 mg, 40 mg, or 100 mg OxyContin. PK concentrations were collected for 18 subjects in the PF614 group (6 subjects in each dose cohort) or six subjects in the OxyContin group (2 subjects in each dose cohort). Oxycodone mean plasma concentrations were above the LLOQ (0.200 ng/mL) within 0.50 h to 1.00 h postdose. LLOQ, lower limit of quantification; PK, pharmacokinetic.

    Techniques Used: Clinical Proteomics

    Summary of oxycodone plasma trough concentrations – part A.
    Figure Legend Snippet: Summary of oxycodone plasma trough concentrations – part A.

    Techniques Used: Clinical Proteomics

    Summary of oxycodone plasma pharmacokinetic parameters: part B.
    Figure Legend Snippet: Summary of oxycodone plasma pharmacokinetic parameters: part B.

    Techniques Used: Clinical Proteomics

    Statistical analysis of bioequivalence on oxycodone for PF614 versus OxyContin: part B.
    Figure Legend Snippet: Statistical analysis of bioequivalence on oxycodone for PF614 versus OxyContin: part B.

    Techniques Used:

    Part B: scatter plot of individual oxycodone. Part A: C max and B: AUC 0–inf values. Individual subject ( n = 57) C max (a) or AUC 0–inf (b) values are plotted for 100 mg PF614 or 40 mg OxyContin dose groups administered in the fed and fasted state. Mean (filled bar) and median (open bar) values are shown for each group. BE between groups is demonstrated by the BE brackets. AUC 0–inf , area under the curve from 0 to infinity; BE, bioequivalence; C max , maximal plasma concentration.
    Figure Legend Snippet: Part B: scatter plot of individual oxycodone. Part A: C max and B: AUC 0–inf values. Individual subject ( n = 57) C max (a) or AUC 0–inf (b) values are plotted for 100 mg PF614 or 40 mg OxyContin dose groups administered in the fed and fasted state. Mean (filled bar) and median (open bar) values are shown for each group. BE between groups is demonstrated by the BE brackets. AUC 0–inf , area under the curve from 0 to infinity; BE, bioequivalence; C max , maximal plasma concentration.

    Techniques Used: Clinical Proteomics, Concentration Assay

    Statistical analysis of food effects on oxycodone bioavailability following oral PF614 or OxyContin: part B.
    Figure Legend Snippet: Statistical analysis of food effects on oxycodone bioavailability following oral PF614 or OxyContin: part B.

    Techniques Used:



    Similar Products

    er oxycodone hydrochloride (oxycontin)  (Purdue Pharma)
    90
    Purdue Pharma er oxycodone hydrochloride (oxycontin)
    Summary of <t> oxycodone </t> plasma PK parameters following PF614 and OxyContin administration (day 1) – part A.
    Er Oxycodone Hydrochloride (Oxycontin), supplied by Purdue Pharma, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/er oxycodone hydrochloride (oxycontin)/product/Purdue Pharma
    Average 90 stars, based on 1 article reviews
    er oxycodone hydrochloride (oxycontin) - by Bioz Stars, 2026-06
    90/100 stars
    		  Buy from Supplier
    oxycontin er  (Purdue Pharma)
    90
    Purdue Pharma oxycontin er
    Summary of <t> oxycodone </t> plasma PK parameters following PF614 and OxyContin administration (day 1) – part A.
    Oxycontin Er, supplied by Purdue Pharma, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/oxycontin er/product/Purdue Pharma
    Average 90 stars, based on 1 article reviews
    oxycontin er - by Bioz Stars, 2026-06
    90/100 stars
    		  Buy from Supplier
    oxycodone hcl er tablets oxycontin  (Purdue Pharma)
    90
    Purdue Pharma oxycodone hcl er tablets oxycontin
    Summary of <t> oxycodone </t> plasma PK parameters following PF614 and OxyContin administration (day 1) – part A.
    Oxycodone Hcl Er Tablets Oxycontin, supplied by Purdue Pharma, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/oxycodone hcl er tablets oxycontin/product/Purdue Pharma
    Average 90 stars, based on 1 article reviews
    oxycodone hcl er tablets oxycontin - by Bioz Stars, 2026-06
    90/100 stars
    		  Buy from Supplier
    oxycontin r© er  (Purdue Pharma)
    90
    Purdue Pharma oxycontin r© er
    Summary of <t> oxycodone </t> plasma PK parameters following PF614 and OxyContin administration (day 1) – part A.
    Oxycontin R© Er, supplied by Purdue Pharma, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/oxycontin r© er/product/Purdue Pharma
    Average 90 stars, based on 1 article reviews
    oxycontin r© er - by Bioz Stars, 2026-06
    90/100 stars
    		  Buy from Supplier
    oxycontin oxycodone er  (Purdue Pharma)
    90
    Purdue Pharma oxycontin oxycodone er
    Summary of <t> oxycodone </t> plasma PK parameters following PF614 and OxyContin administration (day 1) – part A.
    Oxycontin Oxycodone Er, supplied by Purdue Pharma, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/oxycontin oxycodone er/product/Purdue Pharma
    Average 90 stars, based on 1 article reviews
    oxycontin oxycodone er - by Bioz Stars, 2026-06
    90/100 stars
    		  Buy from Supplier
    oxycontin® er 04/2014  (Purdue Pharma)
    90
    Purdue Pharma oxycontin® er 04/2014
    Summary of <t> oxycodone </t> plasma PK parameters following PF614 and OxyContin administration (day 1) – part A.
    Oxycontin® Er 04/2014, supplied by Purdue Pharma, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/oxycontin® er 04/2014/product/Purdue Pharma
    Average 90 stars, based on 1 article reviews
    oxycontin® er 04/2014 - by Bioz Stars, 2026-06
    90/100 stars
    		  Buy from Supplier
    er oxycodone product oxycontin  (Purdue Pharma)
    90
    Purdue Pharma er oxycodone product oxycontin
    Summary of <t> oxycodone </t> plasma PK parameters following PF614 and OxyContin administration (day 1) – part A.
    Er Oxycodone Product Oxycontin, supplied by Purdue Pharma, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/er oxycodone product oxycontin/product/Purdue Pharma
    Average 90 stars, based on 1 article reviews
    er oxycodone product oxycontin - by Bioz Stars, 2026-06
    90/100 stars
    		  Buy from Supplier

    Image Search Results


    Summary of oxycodone plasma PK parameters following PF614 and OxyContin administration (day 1) – part A.

    Journal: Clinical and Translational Science

    Article Title: Clinical evaluation of PF614, a novel TAAP prodrug of oxycodone, versus OxyContin in a multi‐ascending dose study with a bioequivalence arm in healthy volunteers

    doi: 10.1111/cts.13765

    Figure Lengend Snippet: Summary of oxycodone plasma PK parameters following PF614 and OxyContin administration (day 1) – part A.

    Article Snippet: The ER oxycodone hydrochloride (OxyContin; Purdue Pharma) was supplied as 20 and 40 mg tablets that were obtained from commercial sources (Lots WP5J1 and WK8P0A [20 mg] and WM2E1 [40 mg]).

    Techniques: Clinical Proteomics

    Part A: Semi‐log plot of mean (SD) oxycodone plasma concentrations versus time. Part A: day 1 0–12 h; Part B: day 5 0–120 h. Mean plasma concentrations of plasma oxycodone on day 1 (a) versus day 5 (b) are shown following single oral dose administrations of 50 mg, 100 mg, or 200 mg PF614, or 20 mg, 40 mg, or 100 mg OxyContin. PK concentrations were collected for 18 subjects in the PF614 group (6 subjects in each dose cohort) or six subjects in the OxyContin group (2 subjects in each dose cohort). Oxycodone mean plasma concentrations were above the LLOQ (0.200 ng/mL) within 0.50 h to 1.00 h postdose. LLOQ, lower limit of quantification; PK, pharmacokinetic.

    Journal: Clinical and Translational Science

    Article Title: Clinical evaluation of PF614, a novel TAAP prodrug of oxycodone, versus OxyContin in a multi‐ascending dose study with a bioequivalence arm in healthy volunteers

    doi: 10.1111/cts.13765

    Figure Lengend Snippet: Part A: Semi‐log plot of mean (SD) oxycodone plasma concentrations versus time. Part A: day 1 0–12 h; Part B: day 5 0–120 h. Mean plasma concentrations of plasma oxycodone on day 1 (a) versus day 5 (b) are shown following single oral dose administrations of 50 mg, 100 mg, or 200 mg PF614, or 20 mg, 40 mg, or 100 mg OxyContin. PK concentrations were collected for 18 subjects in the PF614 group (6 subjects in each dose cohort) or six subjects in the OxyContin group (2 subjects in each dose cohort). Oxycodone mean plasma concentrations were above the LLOQ (0.200 ng/mL) within 0.50 h to 1.00 h postdose. LLOQ, lower limit of quantification; PK, pharmacokinetic.

    Article Snippet: The ER oxycodone hydrochloride (OxyContin; Purdue Pharma) was supplied as 20 and 40 mg tablets that were obtained from commercial sources (Lots WP5J1 and WK8P0A [20 mg] and WM2E1 [40 mg]).

    Techniques: Clinical Proteomics

    Summary of oxycodone plasma trough concentrations – part A.

    Journal: Clinical and Translational Science

    Article Title: Clinical evaluation of PF614, a novel TAAP prodrug of oxycodone, versus OxyContin in a multi‐ascending dose study with a bioequivalence arm in healthy volunteers

    doi: 10.1111/cts.13765

    Figure Lengend Snippet: Summary of oxycodone plasma trough concentrations – part A.

    Article Snippet: The ER oxycodone hydrochloride (OxyContin; Purdue Pharma) was supplied as 20 and 40 mg tablets that were obtained from commercial sources (Lots WP5J1 and WK8P0A [20 mg] and WM2E1 [40 mg]).

    Techniques: Clinical Proteomics

    Summary of oxycodone plasma pharmacokinetic parameters: part B.

    Journal: Clinical and Translational Science

    Article Title: Clinical evaluation of PF614, a novel TAAP prodrug of oxycodone, versus OxyContin in a multi‐ascending dose study with a bioequivalence arm in healthy volunteers

    doi: 10.1111/cts.13765

    Figure Lengend Snippet: Summary of oxycodone plasma pharmacokinetic parameters: part B.

    Article Snippet: The ER oxycodone hydrochloride (OxyContin; Purdue Pharma) was supplied as 20 and 40 mg tablets that were obtained from commercial sources (Lots WP5J1 and WK8P0A [20 mg] and WM2E1 [40 mg]).

    Techniques: Clinical Proteomics

    Statistical analysis of bioequivalence on oxycodone for PF614 versus OxyContin: part B.

    Journal: Clinical and Translational Science

    Article Title: Clinical evaluation of PF614, a novel TAAP prodrug of oxycodone, versus OxyContin in a multi‐ascending dose study with a bioequivalence arm in healthy volunteers

    doi: 10.1111/cts.13765

    Figure Lengend Snippet: Statistical analysis of bioequivalence on oxycodone for PF614 versus OxyContin: part B.

    Article Snippet: The ER oxycodone hydrochloride (OxyContin; Purdue Pharma) was supplied as 20 and 40 mg tablets that were obtained from commercial sources (Lots WP5J1 and WK8P0A [20 mg] and WM2E1 [40 mg]).

    Techniques:

    Part B: scatter plot of individual oxycodone. Part A: C max and B: AUC 0–inf values. Individual subject ( n = 57) C max (a) or AUC 0–inf (b) values are plotted for 100 mg PF614 or 40 mg OxyContin dose groups administered in the fed and fasted state. Mean (filled bar) and median (open bar) values are shown for each group. BE between groups is demonstrated by the BE brackets. AUC 0–inf , area under the curve from 0 to infinity; BE, bioequivalence; C max , maximal plasma concentration.

    Journal: Clinical and Translational Science

    Article Title: Clinical evaluation of PF614, a novel TAAP prodrug of oxycodone, versus OxyContin in a multi‐ascending dose study with a bioequivalence arm in healthy volunteers

    doi: 10.1111/cts.13765

    Figure Lengend Snippet: Part B: scatter plot of individual oxycodone. Part A: C max and B: AUC 0–inf values. Individual subject ( n = 57) C max (a) or AUC 0–inf (b) values are plotted for 100 mg PF614 or 40 mg OxyContin dose groups administered in the fed and fasted state. Mean (filled bar) and median (open bar) values are shown for each group. BE between groups is demonstrated by the BE brackets. AUC 0–inf , area under the curve from 0 to infinity; BE, bioequivalence; C max , maximal plasma concentration.

    Article Snippet: The ER oxycodone hydrochloride (OxyContin; Purdue Pharma) was supplied as 20 and 40 mg tablets that were obtained from commercial sources (Lots WP5J1 and WK8P0A [20 mg] and WM2E1 [40 mg]).

    Techniques: Clinical Proteomics, Concentration Assay

    Statistical analysis of food effects on oxycodone bioavailability following oral PF614 or OxyContin: part B.

    Journal: Clinical and Translational Science

    Article Title: Clinical evaluation of PF614, a novel TAAP prodrug of oxycodone, versus OxyContin in a multi‐ascending dose study with a bioequivalence arm in healthy volunteers

    doi: 10.1111/cts.13765

    Figure Lengend Snippet: Statistical analysis of food effects on oxycodone bioavailability following oral PF614 or OxyContin: part B.

    Article Snippet: The ER oxycodone hydrochloride (OxyContin; Purdue Pharma) was supplied as 20 and 40 mg tablets that were obtained from commercial sources (Lots WP5J1 and WK8P0A [20 mg] and WM2E1 [40 mg]).

    Techniques: